MLTX

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: ARQT MANE ORKA KRYS KYMR NUVL AXSM BMRN RYTM INCY

| Held by: TCAF VHT ESML NUSC ONEQ OPTZ BBC FHLC TMED WSML

Scroll to Statements

Index	-
Market Cap	1.68B
Enterprise Value	1.42B
Income	-257.08M
Sales	0.00M
Book/sh	3.52
Cash/sh	4.33
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	130
IPO	Oct 20, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	5.78
P/C	4.70
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	8.60
Current Ratio	8.60
Debt/Eq	0.40
LT Debt/Eq	0.39
Option/Short	Yes / Yes

EPS (ttm)	-3.87
EPS next Y	-3.63
EPS next Q	-0.92
EPS this Y	-8.24%
EPS next Y	4.93%
EPS next 5Y	6.41%
EPS past 3/5Y	-27.48% -256.78%
Sales past 3/5Y	- -
EPS Y/Y TTM	-68.11%
Sales Y/Y TTM	-
EPS Q/Q	-54.82%
Sales Q/Q	-
Earnings	May 10 AMC
EPS/Sales Surpr.	-9.89% -

Insider Own	13.60%
Insider Trans	-27.49%
Inst Own	82.09%
Inst Trans	13.78%
ROA	-56.40%
ROE	-77.72%
ROIC	-72.64%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	4.11%
SMA50	10.16%
SMA200	24.79%
Trades

Shs Outstand	72.13M
Shs Float	71.38M
Short Float	9.19%
Short Ratio	6.13
Short Interest	6.56M
52W High	62.75 -67.55%
52W Low	5.95 242.18%
Volatility	5.00% 5.55%
ATR (14)	1.05
RSI (14)	59.68
Beta	1.05
Rel Volume	1.81
Avg Volume	1.07M
Volume	1,937,161

Perf Week	7.44%
Perf Month	14.38%
Perf Quarter	4.89%
Perf Half Y	80.34%
Perf YTD	54.48%
Perf Year	-58.35%
Perf 3Y	-58.73%
Perf 5Y	97.86%
Perf 10Y	-
Recom	1.75
Target Price	31.00
Prev Close	19.93
Price	20.36
Change	2.16%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-23-26	Upgrade	Wolfe Research	Underperform → Outperform	$24
Mar-19-26	Upgrade	Rothschild & Co Redburn	Neutral → Buy	$40
Jan-15-26	Downgrade	Goldman	Neutral → Sell	$10
Jan-09-26	Upgrade	BTIG Research	Neutral → Buy	$24
Nov-03-25	Upgrade	H.C. Wainwright	Neutral → Buy	$30
Oct-02-25	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-01-25	Downgrade	Goldman	Buy → Neutral	$7
Sep-30-25	Downgrade	Wolfe Research	Outperform → Underperform	$2
Sep-30-25	Downgrade	Citigroup	Buy → Neutral	$5
Sep-29-25	Downgrade	Stifel	Buy → Hold	$13
Sep-29-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$10
Sep-29-25	Downgrade	Jefferies	Buy → Hold	$8
Sep-29-25	Downgrade	BTIG Research	Buy → Neutral
Jul-28-25	Initiated	Rothschild & Co Redburn	Neutral	$65
May-19-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$61
Mar-18-25	Initiated	RBC Capital Mkts	Outperform	$67
Jan-17-25	Upgrade	Goldman	Neutral → Buy	$62 → $82
Nov-05-24	Resumed	Wedbush	Outperform	$92 → $73
Aug-26-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-25-24	Initiated	Oppenheimer	Outperform	$104

Show Previous Ratings

Jun-24-26 07:48AM	MLTX Stock Extends Pullback After Biggest Rally In Over 6 Months Following Skin Disease Trial Data A Look At The Latest Development (Stocktwits) -5.75%
Jun-23-26 11:08PM	MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering (GlobeNewswire)
Jun-22-26 04:59PM	MLTX Stock Clocks Best Day In Over 6 Months Whats Driving The Investor Optimism? (Stocktwits) +15.36%
04:01PM	MoonLake Immunotherapeutics Announces Proposed Public Offering (GlobeNewswire)
Jun-21-26 08:52PM	Why Is MLTX Stock Rallying Nearly 20% Overnight? (Stocktwits)
05:00PM	Loading…
05:00PM	MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026 (GlobeNewswire)
Jun-17-26 01:29PM	MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts (Stocktwits)
Jun-08-26 09:17PM	Why Did MLTX Stock Rise After-Hours Today? (Stocktwits)
May-11-26 11:09AM	MoonLake Clears A Key Regulatory Hurdle, And Shares Rocket (Investor's Business Daily) +10.43%
10:16AM	MoonLake (MLTX) Shares Gain After Positive FDA Meeting on Sonelokimab Filing (InvestorsHub)
May-10-26 09:00AM	MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-06-26 06:30AM	Avalo shares spike on skin drug data; BioNTech to cut staff (BioPharma Dive)
Apr-10-26 05:28PM	Southwest Airlines, Colliers International, and More Stocks See Action From Activist Investors (Barrons.com) -7.47%
Mar-31-26 12:44PM	MoonLakes lead asset shows durability in late-stage HS studies (Clinical Trials Arena) +10.10%
Mar-28-26 03:00PM	MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting (GlobeNewswire)
09:39AM	Loading…
Mar-19-26 09:39AM	Micron downgraded, Five Below upgraded: Wall Street's top analyst calls (The Fly)
Mar-02-26 10:23AM	Goldman Questions MoonLake Immunotherapeutics' (MLTX) Sonelokimab Approval Odds Despite Pipeline Update (Insider Monkey)
Feb-24-26 01:16AM	MoonLake Immunotherapeutics Investor Day: HS BLA on Track, axSpA Phase 2 Data Highlights Imaging Wins (MarketBeat)
Feb-23-26 09:10AM	MoonLake Immunotherapeutics Data Shows Phase 2 Success For Chronic Back Pain (Benzinga)
Feb-22-26 11:00AM	MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results (GlobeNewswire)
Feb-03-26 03:48PM	BioTech Breakout: MoonLake Up 30% On FDA Wins (MarketBeat)
Feb-02-26 02:25PM	Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case (Benzinga)
09:36AM	Goldman Sachs Notes VELA-2 Failure, Calls MoonLake Immunotherapeutics (MLTX) a High-Risk Play (Insider Monkey)
08:00AM	MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day (GlobeNewswire)
Jan-15-26 04:33PM	Stocks Boosted by Chip Demand Optimism (Barchart) -6.09%
Jan-09-26 06:28AM	Insmeds ginormous lung drug sales; J&Js US pricing deal (BioPharma Dive) +28.94%
Jan-08-26 02:06PM	MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars (Benzinga) +27.02%
10:19AM	MoonLake Catapults On FDA Deal For Its Down-And-Out Skin Disease Drug (Investor's Business Daily)
08:00AM	MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day (GlobeNewswire)
Dec-15-25 12:00PM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights MLTX (Business Wire)
08:01AM	Loading…
Dec-11-25 08:01AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX (PR Newswire)
Dec-09-25 09:00AM	Investors in MoonLake Immunotherapeutics Should Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - MLTX (PR Newswire)
Dec-08-25 02:26AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX (PR Newswire)
Dec-03-25 03:05PM	MoonLake's (MLTX) SLK Efficacy Claims Under Scrutiny After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority- Hagens Berman (PR Newswire) +6.63%
Dec-02-25 09:00AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - MLTX (PR Newswire) -5.51%
Dec-01-25 08:38PM	MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake's SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority (PR Newswire)
03:18PM	MLTX SHAREHOLDERS: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15 (Newsfile)
04:25AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX (PR Newswire)
Nov-27-25 02:16PM	MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman (Newsfile)
Nov-26-25 08:50AM	MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman (PR Newswire)
Nov-25-25 04:31PM	MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman (PR Newswire)
Nov-21-25 08:45AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MLTX (PR Newswire)
Nov-14-25 09:00AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - MLTX (PR Newswire)
Nov-11-25 04:25AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX (PR Newswire) +8.60%
Nov-07-25 02:49AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX (PR Newswire)
Nov-05-25 07:11AM	MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering (GlobeNewswire)
07:00AM	MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody Sonelokimab (GlobeNewswire)
Oct-29-25 08:46AM	MLTX STOCK LOSS NOTICE: MoonLake Immunotherapeutics Investors are Notified they may have been Affected by Fraud and are Urged to Contact BFA Law (Newsfile)
Oct-28-25 08:55AM	Investors in MoonLake Immunotherapeutics (MLTX): Protect Your Rights - Contact Levi & Korsinsky Before December 15, 2025 (Newsfile)
Oct-22-25 05:47PM	The Best AI for Picking Stocks, Ranked by Performance (MarketBeat)
Oct-16-25 03:14AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX (PR Newswire) -5.16%
Oct-15-25 03:41PM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights MLTX (Business Wire)
Oct-14-25 12:03PM	MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens Berman (PR Newswire)
Oct-01-25 08:12AM	MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens Berman (PR Newswire)
Sep-29-25 05:30PM	Podcast: U.S. Stocks Tick Higher as Government Shutdown Looms (The Wall Street Journal) -89.93% +14.81%
11:46AM	Applovin, furniture stocks, MoonLake: Trending Tickers (Yahoo Finance Video)
09:42AM	UCB Soars to Record as Rival MoonLake Crashes on Trial Data (Bloomberg)
09:38AM	MoonLake Crashes 89% On Mixed Results For Skin Disease Treatment (Investor's Business Daily)
08:40AM	MoonLake Immunotherapeutics Stock Collapses. Why It's Down 88%. (Barrons.com)
Sep-28-25 12:04PM	MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody sonelokimab (GlobeNewswire)
Sep-10-25 12:59AM	Leerink Partners Reiterated a Buy on MoonLake Immunotherapeutics (MLTX) (Insider Monkey)
Aug-27-25 03:32AM	2 Small-Cap Biotech Stocks Well Positioned for a Breakout (Motley Fool)
Aug-16-25 10:41PM	MoonLake Immunotherapeutics (MLTX): A Bull Case Theory (Insider Monkey)
Aug-05-25 07:00AM	MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire)
Jul-31-25 12:33PM	Phase 3 Trials Accelerate MoonLake Advances for Immunologic Disease Treatment (Insider Monkey)
Jul-09-25 01:09AM	Merck nears about $10 billion deal for London-based lung therapy firm Verona, FT reports (Reuters)
Jun-04-25 12:06PM	MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout (Zacks) +5.15%
Jun-03-25 09:33AM	Constellation and Meta, Merck, Snowflake: Trending Tickers (Yahoo Finance Video) +17.95%
09:32AM	MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover (Investor's Business Daily)
09:27AM	MoonLake Immunotherapeutics Catapults On Rumored $3 Billion Merck Takeover Bid (Investor's Business Daily)
07:38AM	Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report (Benzinga)
07:20AM	MoonLake Stock Jumps 23%. Why a $3 Billion Merck Offer Could Be a Win-Win. (Barrons.com)
Jun-02-25 05:08PM	Merck held talks to buy biotech MoonLake for over $3 billion, FT reports (Reuters) +5.51%
May-27-25 03:33PM	H.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PT (Insider Monkey)
May-15-25 09:55AM	Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet (Zacks)
May-12-25 04:00PM	MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-25-25 04:05PM	MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 (GlobeNewswire)
Apr-23-25 12:52PM	Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
Apr-08-25 03:31AM	MoonLake Immunotherapeutics: A Buy At Dips (Seeking Alpha) -5.59%
Apr-03-25 07:00AM	MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates (GlobeNewswire)
Feb-26-25 07:00AM	MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-25-25 09:49AM	Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now? (Insider Monkey)
Feb-23-25 01:33PM	MoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to Analysts (Insider Monkey)
Feb-20-25 12:12PM	MoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy Now (Insider Monkey)
Jan-10-25 07:15AM	MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG (TipRanks)
Jan-08-25 07:00AM	MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody sonelokimab (GlobeNewswire)
Nov-13-24 08:00AM	MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody sonelokimab in patients with active psoriatic arthritis (GlobeNewswire)
Nov-07-24 07:00AM	MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Oct-08-24 09:11PM	Biotechnology Value Fund L.P. Reduces Stake in MoonLake Immunotherapeutics (GuruFocus.com)
Sep-24-24 11:55PM	Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now? (Insider Monkey) -6.36%
Sep-23-24 02:44AM	MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR Stock (Insider Monkey)
Sep-09-24 07:00AM	MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 (GlobeNewswire)
Aug-27-24 08:21PM	MoonLake Immunotherapeutics (MLTX): One of Oppenheimers Top Stock Picks For the Next 12 Months (Insider Monkey)
Aug-07-24 08:00AM	MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 (GlobeNewswire)
Jun-10-24 08:00AM	MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody sonelokimab in Psoriatic Arthritis (GlobeNewswire)
May-16-24 08:00AM	MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (GlobeNewswire)
May-07-24 09:02PM	MoonLake Immunotherapeutics Reports Q1 2024 Financial Outcomes (GuruFocus.com)
01:53PM	MLTX Stock Earnings: MoonLake Misses EPS for Q1 2024 (InvestorPlace)
10:15AM	MoonLake Immunotherapeutics Q1 Net Loss Widens (MT Newswires)
08:00AM	MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

Co-FounderDr. Jorge Santos da Silva Ph.D.

Ph.D.Dr. Kristian Reich M.D.

Chief Financial OfficerMr. Matthias Bodenstedt

Chief Technical OfficerMr. Oliver Daltrop Ph.D.

Director of Investor Relations & External CommunicationsMs. Carla Bretes

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Santos da Silva Jorge	Chief Executive Officer	Jul 01 '26	Sale	20.03	47,775	956,933	2,877,118	Jul 02 04:10 PM
Santos da Silva Jorge	Officer	Jun 30 '26	Proposed Sale	20.03	150,000	3,004,500		Jun 30 05:15 PM
Bodenstedt Matthias	Chief Financial Officer	Jun 22 '26	Sale	22.04	39,120	862,205	1,115,435	Jun 23 04:01 PM
Bodenstedt Matthias	Chief Financial Officer	Jun 17 '26	Sale	19.68	15,082	296,814	1,157,349	Jun 18 06:45 PM
Bodenstedt Matthias	Chief Financial Officer	Jun 18 '26	Sale	19.60	2,794	54,762	1,154,555	Jun 18 06:45 PM
Reich Kristian	Chief Scientific Officer	Jun 17 '26	Sale	19.43	50,000	971,500	2,824,551	Jun 17 06:15 PM
Reich Kristian	Chief Scientific Officer	Jun 15 '26	Sale	18.89	50,000	944,500	2,924,551	Jun 17 06:15 PM
Reich Kristian	Chief Scientific Officer	Jun 16 '26	Sale	18.70	50,000	935,000	2,874,551	Jun 17 06:15 PM
Reich Kristian	Officer	Jun 15 '26	Proposed Sale	19.00	150,000	2,850,000		Jun 15 05:14 PM
Bodenstedt Matthias	Chief Financial Officer	May 11 '26	Sale	20.02	13,653	273,333	1,172,431	May 13 04:10 PM
Bodenstedt Matthias	Chief Financial Officer	Apr 14 '26	Sale	19.56	2,426	47,453	1,186,084	Apr 16 04:10 PM
Santos da Silva Jorge	Chief Executive Officer	Apr 10 '26	Sale	18.41	98,127	1,806,518	2,976,766	Apr 14 05:55 PM
Santos da Silva Jorge	Chief Executive Officer	Apr 13 '26	Sale	18.23	51,873	945,645	2,924,893	Apr 14 05:55 PM
Bodenstedt Matthias	Chief Financial Officer	Apr 09 '26	Sale	18.94	85,870	1,626,378	1,190,435	Apr 10 06:06 PM
Bodenstedt Matthias	Chief Financial Officer	Apr 10 '26	Sale	19.51	1,925	37,557	1,188,510	Apr 10 06:06 PM
Jorge Pedro Santos Radeck D Si	CEO	Apr 10 '26	Proposed Sale	18.58	150,000	2,787,000		Apr 10 09:56 AM
Bodenstedt Matthias	Officer	Apr 09 '26	Proposed Sale	18.46	160,870	2,969,660		Apr 09 04:01 PM
BVF PARTNERS L P/IL	Director	Mar 31 '26	Sale	16.79	3,750,000	62,962,500	1,039,238	Apr 02 04:48 PM
BVF PARTNERS L P/IL	10% Owner	Mar 31 '26	Proposed Sale	16.93	3,750,000	63,487,500		Mar 31 09:18 PM
Santos da Silva Jorge	Chief Executive Officer	Dec 08 '25	Sale	15.08	130,000	1,960,400	2,948,577	Dec 10 04:29 PM
Santos da Silva Jorge	Chief Executive Officer	Dec 09 '25	Sale	14.49	70,000	1,014,300	2,878,577	Dec 10 04:29 PM
Reich Kristian	Chief Scientific Officer	Dec 08 '25	Sale	15.08	130,000	1,960,400	72,908	Dec 10 04:29 PM
Reich Kristian	Chief Scientific Officer	Dec 09 '25	Sale	14.43	72,908	1,052,062	0	Dec 10 04:29 PM
Jorge Pedro Santos Radeck Da S	Officer	Dec 08 '25	Proposed Sale	14.90	200,000	2,980,000		Dec 08 10:36 AM
Kristian Dieter Johannes Reich	Officer	Dec 08 '25	Proposed Sale	14.80	202,908	3,003,038		Dec 08 10:07 AM
Bodenstedt Matthias	Chief Financial Officer	Oct 08 '25	Buy	9.09	10,870	98,808	627,536	Oct 09 09:01 AM
Chen Bihua	Former 10% Owner	Sep 29 '25	Sale	7.21	6,494,151	46,827,628	2,000,000	Oct 01 05:22 PM
Chen Bihua	Former 10% Owner	Sep 30 '25	Sale	6.96	5,827	40,556	1,994,173	Oct 01 05:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MoonLake Immunotherapeutics

Upgrade your Finviz experience